“We applaud the Administration’s focus on out-of-control prescription drug prices and, in particular, the anticompetitive tactics used by brand-name manufacturers to keep drug prices artificially high.  In publishing this database, the FDA will shine a light on one of the more egregious examples of these practices, and we are hopeful that this transparency will lead to changes in behavior by those manufacturers.  While we believe that ultimately ending these abuses will require passage of the CREATES Act, and we were pleased to hear Speaker Ryan’s optimistic words about that bill today, this is a step in the right direction and the FDA deserves credit for this action.”